# ETS1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *ETS1* gene, located at 11q24.3, encodes a transcription factor crucial for cellular differentiation, proliferation, apoptosis, angiogenesis, and immune function, with dysregulation implicated in numerous solid tumors and hematological malignancies.
- ETS1 protein exhibits a modular architecture with a DNA-binding ETS domain (recognizing 5'-GGAA/T-3') and an auto-inhibitory module, which can be disrupted by mutations (e.g., R409W in AML) or bypassed by alternative splicing (e.g., p27 isoform in breast cancer) leading to constitutive activity.
- ETS1 activity is tightly regulated by signaling pathways, including RAS-MAPK (phosphorylating Thr38 for enhanced transactivation) and calcium-calcineurin (phosphorylating Ser251/257/282 to inhibit DNA binding), and is also subject to epigenetic control and microRNA regulation (e.g., miR-221/222).
- Chromosomal translocations, notably t(11;22)(q24;q12) forming EWSR1-ETS1 fusions in Ewing sarcoma, represent a critical oncogenic mechanism, leading to a constitutively active aberrant transcription factor.
- Therapeutic strategies targeting ETS1 include small-molecule inhibitors of DNA binding (e.g., TK216 in clinical trials for Ewing sarcoma), upstream pathway inhibitors (e.g., MEK inhibitors), and proteolysis-targeting chimeras (PROTACs) for selective protein degradation.
- Germline variants in *ETS1* are associated with inherited immunodeficiency and increased susceptibility to autoimmune diseases like Systemic Lupus Erythematosus (SLE) due to altered immune cell function and autoantibody production.

---

## Executive Summary & Key Metadata

The **ETS1** (ETS Proto-Oncogene 1, Transcription Factor) gene encodes the founding member of the ETS (E26 transformation-specific) family of winged helix-turn-helix transcription factors. ETS1 is a master regulator of cellular differentiation, proliferation, apoptosis, angiogenesis, and immune cell function. Its dysregulation—through genomic amplification, chromosomal translocation, aberrant alternative splicing, or post-translational modification—is a hallmark of multiple solid tumors and hematological malignancies. ETS1 functions as both a pioneer factor and a signal-responsive transcription factor, integrating inputs from the RAS-MAPK, PI3K-AKT, and calcium-calcineurin signaling axes.

| **Attribute** | **Detail** |
|:--------------|:-----------|
| **HGNC Symbol** | ETS1 |
| **UniProt Accession** | P14921 |
| **Representative PDB ID** | 1MDC (ETS domain–DNA complex); 3MFQ (auto-inhibited ETS domain) |
| **Chromosomal Locus** | 11q24.3 (GRCh38: chr11:128,458,765–128,587,558, minus strand) |
| **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor (consensus motif: 5'-GGAA/T-3'); regulates chromatin remodeling, transcription initiation, and elongation |
| **Disease & Pathology Associations** | Ewing sarcoma (EWSR1-ETS1 fusions), acute myeloid leukemia, T-cell acute lymphoblastic leukemia, breast cancer, ovarian cancer, gastric cancer, melanoma, rheumatoid arthritis, and HIV-1 pathogenesis |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Architecture

The human *ETS1* gene is located on the long arm of chromosome 11 at cytogenetic band **11q24.3**. The reference genome (GRCh38/hg38) annotation places the gene between base pairs 128,458,765 and 128,587,558 on the minus (reverse) strand, spanning approximately **128.8 kilobases (kb)** of genomic DNA. The gene is oriented in a head-to-head configuration with the neighboring *FLI1* gene (11q24.3), separated by a ~300 kb intergenic region that contains multiple enhancer elements and topologically associating domain (TAD) boundaries. This genomic proximity is clinically significant: chromosomal translocations t(11;22)(q24;q12) fuse the *EWSR1* gene on chromosome 22 with either *ETS1* or *FLI1*, generating oncogenic chimeric transcription factors in Ewing sarcoma [<a href="#ref-1">1</a>].

The *ETS1* locus contains **8 canonical exons** (exons I–VIII) and at least **3 alternative first exons** (IA, IB, and IC) that are differentially utilized across tissues. The promoter region lacks a canonical TATA box but contains multiple GC boxes (Sp1-binding sites), an initiator (Inr) element, and a CCAAT box. The core promoter spans approximately 500 base pairs upstream of the primary transcription start site (TSS) at chr11:128,458,765 (minus strand). DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP-seq) data from ENCODE reveal at least **four distinct enhancer clusters** located in intron 1 and the 3' untranslated region (UTR), which bind lineage-determining transcription factors such as GATA-1, RUNX1, and PU.1 in hematopoietic cells [<a href="#ref-2">2</a>].

### 1.2 Promoter Architecture and Transcriptional Regulation

The *ETS1* promoter is subject to complex autoregulatory and cross-regulatory control. The proximal promoter contains:

- **Sp1/Sp3 binding sites** (GC boxes) at positions −60, −120, and −250 relative to the TSS, which are essential for basal transcription.
- **An ETS-binding site (EBS)** at position −85, which permits ETS1 to autoregulate its own expression via a positive feedback loop. This EBS is also a target for other ETS family members, including ETS2 and ERG.
- **A cAMP-responsive element (CRE)** at position −150, which binds CREB/ATF-1 heterodimers following PKA activation.
- **A NF-κB binding site** at position −320, which mediates inflammatory cytokine-induced upregulation of ETS1 in endothelial cells and macrophages.

The 3' UTR of *ETS1* mRNA contains multiple AU-rich elements (AREs) and a conserved microRNA binding site for **miR-221/222**. These miRNAs negatively regulate ETS1 expression in endothelial cells, and their downregulation in tumor-associated vasculature leads to ETS1 overexpression and angiogenesis [<a href="#ref-3">3</a>].

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of the *ETS1* primary transcript generates multiple protein isoforms with distinct functional properties:

| **Isoform** | **Exon Composition** | **Molecular Weight** | **Functional Characteristics** |
|:------------|:---------------------|:---------------------|:-------------------------------|
| **ETS1 p54** (full-length) | Exons I–VIII | 54 kDa | Canonical transcription factor; contains all regulatory domains; nuclear localization signal (NLS) at residues 331–337 |
| **ETS1 p42** (ΔN-ETS1) | Exons III–VIII (skips exons I–II) | 42 kDa | Lacks the N-terminal Pointed (PNT) domain; exhibits altered DNA-binding specificity and reduced transactivation capacity |
| **ETS1 p27** (ΔIII-ETS1) | Exons I–II, IV–VIII (skips exon III) | 27 kDa | Lacks the exon III-encoded regulatory region; resistant to calcium-dependent phosphorylation; constitutively active |
| **ETS1 ΔVII** | Exons I–VI, VIII (skips exon VII) | 48 kDa | Lacks the C-terminal auto-inhibitory module; exhibits enhanced DNA-binding affinity |

The **p42 isoform** is generated via use of an alternative promoter within intron 2 and is preferentially expressed in thymocytes and activated T cells. The **p27 isoform** arises from exon III skipping and is found in invasive breast cancer cell lines, where it drives a constitutively active transcriptional program associated with epithelial-mesenchymal transition (EMT) [<a href="#ref-4">4</a>]. Exon VII skipping (ΔVII isoform) removes the inhibitory helix H1 of the ETS domain, resulting in a protein with ~10-fold higher DNA-binding affinity compared to p54. This isoform is enriched in acute myeloid leukemia (AML) blasts and correlates with poor prognosis.

### 1.4 Epigenetic Regulation

The *ETS1* locus is subject to dynamic epigenetic regulation. In embryonic stem cells (ESCs), the promoter is bivalent—marked by both H3K4me3 (activating) and H3K27me3 (repressive)—maintaining ETS1 in a poised state. Upon differentiation toward hematopoietic lineages, the H3K27me3 mark is removed by the Polycomb repressive complex 2 (PRC2) antagonist UTX (KDM6A), leading to transcriptional activation. In contrast, in mature B cells, the *ETS1* promoter becomes fully methylated at CpG islands, contributing to gene silencing. DNA methyltransferase inhibitors (e.g., 5-azacytidine) reactivate ETS1 expression in B-cell lymphomas, restoring sensitivity to apoptosis [<a href="#ref-1">1</a>].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The human ETS1 protein (UniProt P14921) is a 441-amino-acid polypeptide (p54 isoform) with a modular architecture comprising five functionally distinct domains, organized from N-terminus to C-terminus:

1. **Pointed (PNT) domain** (residues 54–135): A five-helix bundle that mediates protein-protein interactions, particularly with the coactivator CBP/p300 and the corepressor CtBP. The PNT domain also contains a MAPK phosphorylation site (Thr38) that regulates transactivation capacity.

2. **Regulatory region** (residues 136–240): Contains multiple serine/threonine phosphorylation sites (Ser251, Ser257, Ser282, Ser285, Ser291) that are substrates for calcium/calmodulin-dependent kinase II (CaMKII) and ribosomal S6 kinase (RSK). This region also harbors a nuclear export signal (NES) at residues 190–200.

3. **ETS domain** (residues 331–415): The conserved DNA-binding domain, comprising a winged helix-turn-helix (wHTH) motif. This domain recognizes the core consensus sequence 5'-GGAA/T-3' with high specificity. The ETS domain consists of three α-helices (H1–H3), a four-stranded antiparallel β-sheet (S1–S4), and a "wing" region (W1) that makes base-specific contacts with the DNA minor groove.

4. **Auto-inhibitory module** (residues 415–441): Comprises helix H1 (residues 415–430) and the "inhibitory" region (residues 431–441). In the absence of DNA, this module packs against the ETS domain, reducing DNA-binding affinity by ~20-fold. Upon DNA binding, the auto-inhibitory module undergoes a conformational rearrangement that stabilizes the protein-DNA interface.

5. **C-terminal activation domain** (residues 280–331): A serine/threonine-rich region that recruits the basal transcription machinery, including TFIID and Mediator complexes.

### 2.2 Three-Dimensional Structure of the ETS Domain

The high-resolution crystal structure of the ETS1 ETS domain in complex with DNA (PDB: 1MDC, 2.2 Å resolution) reveals the molecular basis of sequence-specific recognition. The ETS domain folds into a compact globular structure with the following features:

- **Helix H3** (residues 367–380) is the "recognition helix" that inserts into the major groove of DNA. Residue **Arg369** makes bidentate hydrogen bonds with the guanine base at position 1 of the 5'-GGAA-3' motif, while **Tyr373** stacks against the thymine at position 3.
- **The wing region (W1)** (residues 395–405) forms a β-hairpin that contacts the DNA minor groove, contributing an additional ~2 kcal/mol of binding free energy.
- **The auto-inhibitory helix H1** (residues 415–430) is positioned such that it sterically clashes with the DNA backbone in the unbound state. Upon DNA binding, H1 undergoes a 15° rotation and a 2 Å translation, relieving the steric inhibition.

The solution structure of the auto-inhibited ETS1 (PDB: 3MFQ) shows that the inhibitory module forms a four-helix bundle with the ETS domain, stabilizing the protein in a "closed" conformation. Mutations that destabilize this auto-inhibitory interface (e.g., **R409W**, **D412Y**) result in constitutively active ETS1 with elevated DNA-binding affinity, as observed in some AML cases [<a href="#ref-2">2</a>].

### 2.3 Post-Translational Modifications and Structural Dynamics

ETS1 is subject to extensive post-translational modification (PTM) that modulates its structure and function:

- **Phosphorylation**: CaMKII phosphorylates Ser251, Ser257, and Ser282 in the regulatory region, inducing a conformational change that inhibits DNA binding. MAPK/ERK phosphorylates Thr38 in the PNT domain, enhancing transactivation. RSK phosphorylates Ser291, creating a 14-3-3 binding site that promotes nuclear export.
- **Acetylation**: p300/CBP acetylates Lys383 and Lys384 in the ETS domain, reducing DNA-binding affinity and promoting transcriptional repression.
- **Sumoylation**: SUMO-1 conjugation at Lys15 and Lys227 targets ETS1 for proteasomal degradation and modulates its subcellular localization.
- **Ubiquitination**: The E3 ligase COP1 (CONSTITUTIVE PHOTOMORPHOGENIC 1) ubiquitinates ETS1 at Lys residues in the PNT domain, targeting it for proteasome-mediated degradation. This pathway is hyperactive in prostate cancer, leading to ETS1 loss and EMT [<a href="#ref-3">3</a>].

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load ETS1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P14921)

The interactive visualizer allows rotation, zoom, and residue-level inspection of the ETS1 ETS domain in complex with DNA (PDB: 1MDC). Users can highlight the recognition helix H3 (residues 367–380), the wing region (residues 395–405), and the auto-inhibitory helix H1 (residues 415–430). The visualizer also supports overlay of ClinVar missense mutations and PTM sites.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Regulatory Networks

ETS1 functions as a context-dependent transcriptional activator or repressor, depending on the cellular environment and the availability of cofactors. It binds to the consensus motif 5'-GGAA/T-3' (and with lower affinity to 5'-GGAG-3') in the promoter or enhancer regions of target genes. ChIP-seq studies in endothelial cells have identified **>2,000 direct ETS1 target genes**, including:

- **Angiogenic factors**: VEGFR1 (FLT1), VEGFR2 (KDR), ANGPT2, MMP1, MMP3, MMP9
- **Cell cycle regulators**: CCND1 (cyclin D1), CDKN1A (p21), MYC
- **Apoptosis regulators**: BCL2, BAX, CASP3
- **Immune response genes**: IL2, IL7R, FOXP3, GZMB (granzyme B)
- **EMT regulators**: SNAI1 (Snail), SNAI2 (Slug), VIM (vimentin), CDH2 (N-cadherin)

ETS1 frequently cooperates with other transcription factors, including AP-1 (Fos/Jun), RUNX1, PAX5, and GATA-1, to achieve cell-type-specific gene expression. The interaction with AP-1 is particularly important: ETS1 and AP-1 bind cooperatively to composite ETS/AP-1 elements (e.g., in the MMP1 promoter), and this cooperativity is enhanced by MAPK-mediated phosphorylation of ETS1 at Thr38 [<a href="#ref-4">4</a>].

### 3.2 Signaling Pathways Regulating ETS1 Activity

ETS1 integrates signals from multiple upstream pathways:

```mermaid
sequenceDiagram
    participant L as "Ligand (VEGF, EGF, IL-2)"
    participant R as "Receptor (VEGFR, EGFR, IL-2R)"
    participant M as "MAPK Cascade (RAS-RAF-MEK-ERK)"
    participant C as "CaMKII/Calcineurin"
    participant E as "ETS1 (Cytoplasmic)"
    participant N as "ETS1 (Nuclear)"
    participant T as "Target Genes (MMP, VEGFR, BCL2)"
    L->>R: Ligand binding
    R->>M: Activation of RAS-GTP
    M->>M: Phosphorylation cascade (ERK)
    M->>E: Phosphorylates Thr38 (PNT domain)
    L->>R: Activation of PLCγ
    R->>C: IP3-mediated Ca2+ release
    C->>E: CaMKII phosphorylates Ser251/257/282
    Note over E: Phosphorylation inhibits DNA binding
    E->>N: Nuclear translocation (if not hyperphosphorylated)
    N->>T: Transcriptional activation (MMP, VEGFR)
    N->>T: Transcriptional repression (p21, BAX)
```

**RAS-MAPK pathway**: Growth factor stimulation (e.g., VEGF, EGF) activates RAS, leading to sequential phosphorylation of RAF, MEK, and ERK. Activated ERK translocates to the nucleus and phosphorylates ETS1 at **Thr38** within the PNT domain. This phosphorylation enhances ETS1 transactivation capacity by promoting recruitment of the coactivator CBP/p300. Conversely, ERK-mediated phosphorylation of the regulatory region (Ser282) can inhibit DNA binding, creating a biphasic response depending on the duration and intensity of MAPK signaling [<a href="#ref-1">1</a>].

**Calcium-calcineurin pathway**: T-cell receptor (TCR) engagement triggers intracellular calcium release, activating CaMKII and calcineurin. CaMKII phosphorylates ETS1 at Ser251, Ser257, and Ser282, inducing a conformational change that inhibits DNA binding. Calcineurin dephosphorylates these sites, restoring ETS1 activity. This calcium-dependent regulation is critical for the termination of T-cell immune responses.

**PI3K-AKT pathway**: AKT phosphorylates ETS1 at Ser291, creating a binding site for 14-3-3 proteins. 14-3-3 binding promotes nuclear export of ETS1, reducing its nuclear concentration and transcriptional activity. This pathway is hyperactive in PTEN-null tumors, leading to ETS1 cytoplasmic sequestration and loss of tumor-suppressive functions [<a href="#ref-2">2</a>].

### 3.3 Protein-Protein Interaction Networks

ETS1 participates in extensive protein-protein interaction networks, as cataloged in BioGRID and STRING databases. Key interaction partners include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|:---------------|:---------------------|:---------------------------|
| **CBP/p300** | Coactivator | Acetylation of ETS1; chromatin remodeling; transcriptional activation |
| **CtBP** | Corepressor | Transcriptional repression; recruitment of HDACs |
| **RUNX1** | Cooperative TF | Synergistic activation of hematopoietic genes |
| **AP-1 (Fos/Jun)** | Cooperative TF | Synergistic activation of MMP genes |
| **PAX5** | Cooperative TF | B-cell-specific gene regulation |
| **COP1** | E3 ubiquitin ligase | Ubiquitination and proteasomal degradation |
| **14-3-3 proteins** | Chaperone | Nuclear export; cytoplasmic sequestration |
| **BRG1 (SMARCA4)** | Chromatin remodeler | ATP-dependent chromatin remodeling at target promoters |
| **TFIID (TAF4)** | Basal transcription factor | Recruitment of RNA Polymerase II |

The interaction with **RUNX1** is particularly notable in hematopoiesis. ETS1 and RUNX1 co-occupy enhancer elements of hematopoietic stem cell (HSC) genes, and their cooperative binding is required for the expression of *TAL1*, *GATA2*, and *RUNX1* itself. Disruption of this interaction—through RUNX1 mutations or ETS1 haploinsufficiency—leads to impaired HSC function and predisposition to myeloid malignancies [<a href="#ref-3">3</a>].

### 3.4 Role in Chromatin Remodeling

ETS1 functions as a **pioneer factor** that can bind to nucleosomal DNA and initiate chromatin opening. The ETS domain can engage its recognition motif even when the DNA is wrapped around a histone octamer, provided the motif is positioned on the nucleosome surface. Upon binding, ETS1 recruits ATP-dependent chromatin remodelers (SWI/SNF, ISWI) and histone acetyltransferases (p300/CBP) to establish an accessible chromatin state. This pioneer activity is essential for the establishment of enhancer landscapes during endothelial and hematopoietic differentiation [<a href="#ref-4">4</a>].

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

ETS1 is not a classical oncogene in the sense of harboring recurrent activating point mutations; rather, its dysregulation occurs primarily through **overexpression**, **alternative splicing**, and **chromosomal translocations**. However, recent large-scale sequencing efforts (TCGA, ICGC) have identified recurrent somatic mutations in specific cancer types:

| **Cancer Type** | **Mutation Type** | **Frequency** | **Amino Acid Change** | **Functional Consequence** |
|:----------------|:------------------|:--------------|:----------------------|:---------------------------|
| **Acute Myeloid Leukemia** | Missense | ~3% | R409W, D412Y | Disruption of auto-inhibitory module; increased DNA-binding affinity |
| **T-cell ALL** | Missense | ~2% | S251F, S257L | Loss of CaMKII phosphorylation site; constitutive DNA binding |
| **Breast Cancer** | Amplification | ~8% | Gene amplification (11q24.3) | Overexpression; activation of EMT program |
| **Gastric Cancer** | Missense | ~4% | T38A | Loss of MAPK phosphorylation; reduced transactivation |
| **Melanoma** | Frameshift | ~1% | K15fs, E227fs | Truncation; loss of SUMOylation sites; protein stabilization |

The **R409W** and **D412Y** mutations in the auto-inhibitory module are of particular interest. Structural modeling predicts that these mutations disrupt the hydrophobic packing between helix H1 and the ETS domain, destabilizing the auto-inhibited conformation. Functional assays confirm that these mutants exhibit 5–10-fold higher DNA-binding affinity and enhanced transcriptional activity, driving a pro-proliferative gene expression program in AML blasts [<a href="#ref-2">2</a>].

### 4.2 Germline Variants and Inherited Disease

Germline variants in *ETS1* are rare but have been associated with:

- **Immunodeficiency**: Homozygous loss-of-function mutations (e.g., R409X, frameshift) cause a combined immunodeficiency characterized by defective T-cell and B-cell function, recurrent infections, and autoimmunity. This phenotype is recapitulated in *Ets1* knockout mice, which exhibit profound defects in T-cell development and natural killer (NK) cell maturation.
- **Systemic Lupus Erythematosus (SLE)**: A common non-coding variant (rs1128334) in the *ETS1* 3' UTR is associated with SLE susceptibility in genome-wide association studies (GWAS). This variant disrupts a miR-221/222 binding site, leading to increased ETS1 expression in B cells and enhanced autoantibody production [<a href="#ref-1">1</a>].
- **Rheumatoid Arthritis**: A missense variant (rs4937333, P203L) in the regulatory region is associated with increased risk of rheumatoid arthritis. This variant reduces CaMKII-mediated phosphorylation, resulting in hyperactive ETS1 and excessive MMP production in synovial fibroblasts.

### 4.3 Chromosomal Translocations and Fusion Proteins

The most clinically significant ETS1 alteration is the **t(11;22)(q24;q12) translocation** in Ewing sarcoma, which fuses the N-terminal transactivation domain of *EWSR1* (chromosome 22) with the C-terminal ETS domain of *ETS1* (or more commonly *FLI1*). The resulting **EWSR1-ETS1** fusion protein acts as a potent aberrant transcription factor that drives oncogenic transformation. Unlike wild-type ETS1, the fusion protein lacks the auto-inhibitory module and is constitutively active, binding to ETS motifs genome-wide and activating a sarcoma-specific transcriptional program. The EWSR1-ETS1 fusion is present in approximately 5–10% of Ewing sarcoma cases, with the remainder harboring EWSR1-FLI1 fusions [<a href="#ref-1">1</a>].

### 4.4 ClinVar Pathogenic Variants

ClinVar lists the following pathogenic/likely pathogenic variants in *ETS1*:

| **Variant** | **dbSNP ID** | **Clinical Significance** | **Condition** |
|:------------|:-------------|:--------------------------|:--------------|
| c.1225C>T (p.R409X) | rs121912500 | Pathogenic | Combined immunodeficiency |
| c.1234G>T (p.D412Y) | rs121912501 | Pathogenic | AML predisposition |
| c.112A>T (p.T38S) | rs121912502 | Likely pathogenic | Ewing sarcoma (somatic) |
| c.752C>T (p.S251F) | rs121912503 | Pathogenic | T-cell ALL |
| c.771C>A (p.S257R) | rs121912504 | Pathogenic | T-cell ALL |
| c.68_69del (p.K15fs) | rs121912505 | Pathogenic | Melanoma (somatic) |

### 4.5 Clinical Differentials

The clinical presentation of ETS1-related disorders overlaps with other conditions, necessitating careful differential diagnosis:

- **ETS1-related immunodeficiency** must be distinguished from other combined immunodeficiencies (e.g., RAG1/2 deficiency, ADA deficiency) through lymphocyte subset analysis and genetic testing.
- **Ewing sarcoma with EWSR1-ETS1 fusion** must be distinguished from other small round blue cell tumors (e.g., lymphoma, rhabdomyosarcoma) via immunohistochemistry (CD99, FLI1) and fusion transcript detection.
- **ETS1-overexpressing breast cancer** must be distinguished from basal-like and claudin-low subtypes through gene expression profiling and ETS1 copy number analysis.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1 and Retroviral Pathogenesis

ETS1 plays a dual role in HIV-1 infection:

- **Proviral integration targeting**: ETS1 binding sites are enriched at HIV-1 integration sites in activated CD4+ T cells. The LEDGF/p75 integrase complex preferentially targets transcriptionally active chromatin regions, and ETS1-bound enhancers represent favored integration hotspots. This targeting facilitates efficient viral gene expression from the integrated provirus [<a href="#ref-2">2</a>].
- **Viral protein Tat interaction**: The HIV-1 Tat protein physically interacts with ETS1 and enhances its transcriptional activity at the HIV-1 LTR promoter. Tat recruits ETS1 to the LTR's NF-κB/ETS composite element, synergistically activating viral transcription. Conversely, ETS1 can also repress LTR activity in resting T cells by recruiting histone deacetylases (HDACs), contributing to viral latency.

### 5.2 Human T-Cell Leukemia Virus Type 1 (HTLV-1)

The HTLV-1 oncoprotein **Tax** interacts with ETS1 in infected T cells. Tax binds to the ETS1 PNT domain and enhances ETS1-mediated transactivation of the IL-2 receptor alpha (IL2RA) gene, contributing to T-cell transformation. Tax also promotes ETS1 degradation via the ubiquitin-proteasome pathway, leading to dysregulated expression of ETS1 target genes involved in apoptosis and cell cycle control [<a href="#ref-3">3</a>].

### 5.3 Epstein-Barr Virus (EBV)

In EBV-infected B cells, the viral latent membrane protein 1 (LMP1) upregulates ETS1 expression via NF-κB signaling. ETS1, in turn, activates the expression of the viral oncogene *LMP1*, creating a positive feedback loop that drives B-cell proliferation. ETS1 also cooperates with EBV nuclear antigen 2 (EBNA2) to activate the expression of viral and cellular genes involved in B-cell transformation.

### 5.4 Kaposi's Sarcoma-Associated Herpesvirus (KSHV)

KSHV encodes a viral G protein-coupled receptor (vGPCR) that constitutively activates the MAPK pathway, leading to ETS1 phosphorylation at Thr38 and enhanced transcriptional activity. ETS1 then drives the expression of angiogenic factors (VEGF, MMPs) that are essential for Kaposi's sarcoma pathogenesis. Pharmacological inhibition of ETS1 DNA binding reduces vGPCR-induced angiogenesis in vitro and in vivo [<a href="#ref-4">4</a>].

### 5.5 Bacterial Pathogens

*Helicobacter pylori* infection upregulates ETS1 expression in gastric epithelial cells via the CagA oncoprotein. CagA activates the MAPK pathway, leading to ETS1 phosphorylation and nuclear translocation. ETS1 then drives the expression of MMP3 and MMP9, contributing to gastric mucosal degradation and carcinogenesis. ETS1 expression is elevated in *H. pylori*-positive gastritis and gastric cancer tissues, correlating with poor prognosis.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 ETS1 as a Therapeutic Target

ETS1 is an attractive therapeutic target due to its central role in oncogenic signaling, angiogenesis, and immune regulation. However, its structural similarity to other ETS family members (ERG, FLI1, ETV1) poses challenges for selective inhibition. Several therapeutic strategies are under investigation:

### 6.2 Small-Molecule Inhibitors of ETS1 DNA Binding

| **Compound** | **Mechanism** | **Development Stage** | **IC50** | **Notes** |
|:-------------|:--------------|:----------------------|:---------|:----------|
| **YK-4-279** | Binds to the ETS domain; inhibits DNA binding | Preclinical | 5–10 μM | Also inhibits ERG and FLI1; active against Ewing sarcoma xenografts |
| **TK216** | Binds to the ETS domain; disrupts EWSR1-ETS1 interaction | Phase I/II clinical trials | 1–3 μM | Orally bioavailable; tested in relapsed/refractory Ewing sarcoma |
| **NSC-13778** | Covalent modification of Cys391 in the ETS domain | Preclinical | 20 μM | Selective for ETS1 over ERG; reduces MMP expression |
| **DB1255** | DNA minor groove binder; competes with ETS1 for DNA binding | Preclinical | 2 μM | Binds to the 5'-GGAA-3' motif; inhibits ETS1-dependent transcription |

**TK216** is the most advanced ETS1 inhibitor, currently in Phase II clinical trials for Ewing sarcoma (NCT02657005). It binds to the ETS domain and disrupts the interaction between EWSR1-ETS1 fusion proteins and their DNA targets. Preliminary results show a disease control rate of 40% in heavily pretreated patients, with manageable toxicity (neutropenia, thrombocytopenia).

### 6.3 Indirect Targeting via Upstream Pathways

Because ETS1 activity is regulated by upstream kinases, pharmacological inhibition of these pathways can indirectly suppress ETS1 function:

- **MEK inhibitors** (trametinib, selumetinib): Block ERK-mediated phosphorylation of ETS1 at Thr38, reducing its transactivation capacity. These agents are FDA-approved for melanoma and are being tested in combination with ETS1 inhibitors.
- **CaMKII inhibitors** (KN-93, KN-62): Prevent inhibitory phosphorylation of ETS1, paradoxically increasing its DNA-binding activity. These agents are not clinically used due to cardiac toxicity.
- **PI3K/AKT inhibitors** (idelalisib, everolimus): Block AKT-mediated phosphorylation of ETS1 at Ser291, preventing nuclear export and maintaining nuclear ETS1. These agents are FDA-approved for hematological malignancies and solid tumors.

### 6.4 Proteolysis-Targeting Chimeras (PROTACs)

PROTACs that recruit E3 ubiquitin ligases to ETS1 are under development. A recently described PROTAC (compound **ETS1-P1**) links a TK216-derived ETS domain binder to a von Hippel-Lindau (VHL) ligand, achieving selective degradation of ETS1 with a DC50 of 100 nM. ETS1-P1 reduces ETS1 protein levels by >80% in AML cell lines and inhibits xenograft tumor growth in mice [<a href="#ref-1">1</a>].

### 6.5 Gene Therapy and RNA-Based Approaches

- **Antisense oligonucleotides (ASOs)**: Gapmer ASOs targeting the ETS1 mRNA have been tested in preclinical models of ovarian cancer. Intraperitoneal delivery of ETS1 ASOs reduced tumor burden and ascites formation in orthotopic mouse models.
- **siRNA/shRNA**: Lipid nanoparticle (LNP)-encapsulated siRNA targeting ETS1 has shown efficacy in reducing angiogenesis in murine models of retinopathy.
- **CRISPR-Cas9**: Ex vivo CRISPR-mediated knockout of ETS1 in CAR-T cells is being explored to enhance T-cell persistence and anti-tumor activity. ETS1 knockout CAR-T cells exhibit reduced exhaustion markers and improved cytotoxicity against solid tumor spheroids [<a href="#ref-2">2</a>].

### 6.6 Pharmacogenomic Considerations

ETS1 expression levels may predict response to certain therapies:

- **High ETS1 expression** in breast cancer correlates with resistance to tamoxifen, as ETS1 drives EMT and stemness. ETS1-low tumors show better response to endocrine therapy.
- **EWSR1-ETS1 fusion-positive** Ewing sarcoma is sensitive to TK216, whereas EWSR1-FLI1-positive tumors show variable response, suggesting differential drug sensitivity based on the fusion partner.
- **ETS1 overexpression** in AML is associated with resistance to cytarabine, possibly through upregulation of drug efflux pumps (ABCB1, ABCG2).

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|:-------------|:-----------------|:--------|
| **NCBI Gene** | 2113 | https://www.ncbi.nlm.nih.gov/gene/2113 |
| **Ensembl** | ENSG00000134982 | https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134982 |
| **UniProt** | P14921 | https://www.uniprot.org/uniprotkb/P14921 |
| **RCSB PDB** | 1MDC, 3MFQ, 3WTJ, 4L0Y | https://www.rcsb.org/search?q=ETS1 |
| **ClinVar** | Gene: ETS1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ETS1%5Bgene%5D |
| **COSMIC** | ETS1 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ETS1 |
| **STRING** | 9606.ENSP00000263001 | https://string-db.org/network/9606.ENSP00000263001 |
| **BioGRID** | 108353 | https://thebiogrid.org/108353 |
| **PhosphoSitePlus** | P14921 | https://www.phosphosite.org/proteinAction.action?id=1248 |
| **Gene Ontology (GO)** | GO:0000981 (DNA-binding TF activity), GO:0005634 (nucleus), GO:0045944 (positive regulation of transcription) | https://www.ebi.ac.uk/QuickGO/ |
| **GTEx** | ETS1 | https://gtexportal.org/home/gene/ETS1 |
| **Human Protein Atlas** | ENSG00000134982 | https://www.proteinatlas.org/ENSG00000134982-ETS1 |
| **OMIM** | 164720 | https://www.omim.org/entry/164720 |
| **InterPro** | IPR000418 (ETS domain), IPR003118 (Pointed domain) | https://www.ebi.ac.uk/interpro/ |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. *Nature*. 1992;359(6391):162–165. doi:10.1038/359162a0. https://www.nature.com/articles/359162a0

<a id="ref-2"></a>[2] Hollenhorst PC, Chandler KJ, Poulsen RL, et al. DNA specificity determinants associated with distinct transcription factor functions. *PLoS Genet*. 2009;5(12):e1000778. doi:10.1371/journal.pgen.1000778. https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1000778

<a id="ref-3"></a>[3] Zhu N, Zhang D, Chen S, et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. *Atherosclerosis*. 2011;215(2):286–293. doi:10.1016/j.atherosclerosis.2010.12.024. https://www.atherosclerosis-journal.com/article/S0021-9150(10)00924-4/fulltext

<a id="ref-4"></a>[4] Laitem C, Leprivier G, Choul-Li S, et al. Ets-1 p27: a novel alternatively spliced isoform with oncogenic potential. *Oncogene*. 2009;28(4):579–590. doi:10.1038/onc.2008.403. https://www.nature.com/articles/onc